TapImmune Inc. Announces Availability of New Investor Information
July 17, 2007
VANCOUVER, British Columbia, July 17, 2007 (PRIME NEWSWIRE) — TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has launched a new corporate website with links to media features on its technologies.
“I am pleased to have this resource available to our shareholders and other interested parties as it provides a comprehensive look at the company and our technology,” said TapImmune Inc. CEO Denis Corin. “I would like to encourage our shareholders to re-familiarize themselves with our core initiatives and how we are moving forward. In particular I would direct them to look over the articles featured in third party publications as I believe they offer an objective point of view and provide additional credibility to our science.”
“This informational asset is but the first in many steps we will make to assist investors in following TapImmune as we continue to execute our business plan,” Corin added. “We believe that the transparency in our proactive approach should signal to the investing public our confidence and expectations. We encourage you to follow us, to share our story with others who might be interested in our technology and to stay tuned for a regular stream of discourse from TapImmune.”
TapImmune’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local newspapers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others.
The Company is preparing to move its technology to its own facilities and to advance the pre-clinical programs of its core TAP technologies into GLP clinical programs.
Transporters Associated with Antigen Processing (TAP) are ABC transporters responsible for supplying tumor-associated antigens and viral antigens used in the assembly of MHC class I surface molecules. MHC class I molecules are required for the recognition and destruction of tumor cells and virus infected cells by the cellular arm of the immune system. A wide variety of metastatic cancers evade destruction by the immune system due to absent or insufficient amounts of TAP, making the tumors unrecognizable by the immune system. The TAP molecule also works as an adjuvant to enhance vaccines against infectious diseases.
About TapImmune Inc.
TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The companies’ lead product, the AdhTAP vaccine enhancer restores and augments antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of a Phase I clinical trial.
The TapImmune Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3877
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-KSB and other SEC filings which are available through EDGAR at http://www.sec.gov. These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.